8BP Stock Overview
Biocorp Production designs, develops, and manufactures medical devices in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 8BP from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Biocorp Production Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €34.00 |
| 52 Week High | €35.00 |
| 52 Week Low | €13.65 |
| Beta | 0.96 |
| 1 Month Change | -2.30% |
| 3 Month Change | 0.29% |
| 1 Year Change | 149.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8BP | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | 0.3% |
| 1Y | 149.1% | -9.1% | 6.9% |
Return vs Industry: 8BP exceeded the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: 8BP exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 8BP volatility | |
|---|---|
| 8BP Average Weekly Movement | 1.6% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8BP has not had significant price volatility in the past 3 months.
Volatility Over Time: 8BP's weekly volatility has decreased from 7% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 75 | Eric Dessertenne | biocorpsys.com |
Biocorp Production designs, develops, and manufactures medical devices in France. The company provides Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Datapen, a motor driven pen injector; and Injay which collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as NEWGUARD, a safety device compatible with various sizes of prefilled syringes; BIOPASS, a reconstitution system with a needle; Sween, a device that provides real assistance in the administration of medication and closure systems.
Biocorp Production Fundamentals Summary
| 8BP fundamental statistics | |
|---|---|
| Market cap | €154.53m |
| Earnings (TTM) | -€2.14m |
| Revenue (TTM) | €12.80m |
12.1x
P/S Ratio-72.3x
P/E RatioIs 8BP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8BP income statement (TTM) | |
|---|---|
| Revenue | €12.80m |
| Cost of Revenue | €5.24m |
| Gross Profit | €7.56m |
| Other Expenses | €9.70m |
| Earnings | -€2.14m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 59.05% |
| Net Profit Margin | -16.68% |
| Debt/Equity Ratio | 234.8% |
How did 8BP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/12 16:15 |
| End of Day Share Price | 2023/09/28 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocorp Production is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christophe Dombu Youta | Aurgalys SAS |
| Khalid Deojee | Bryan Garnier & Co |
| Stephanie Lefebvre | Gilbert Dupont |